USP30 and paraganglioma: The results of the differential expression analysis indicate that USP30-AS1 exhibits differential expression across multiple cancer cohorts, except for uterine carcinosarcoma (UCS), pheochromocytoma and paraganglioma (PCPG), adrenocortical carcinoma (ACC), and kidney chromophobe (KICH).